Preview Mode Links will not work in preview mode

Nov 1, 2024

Featuring perspectives from Prof Francois-Clement Bidard and Dr Kevin Kalinsky, including the following topics:

  • Introduction: Confronting Metastatic Breast Cancer (mBC) (0:00)
  • Mechanisms of Resistance to Endocrine Therapy in HR-Positive mBC; Use of Oral Selective Estrogen Receptor Degraders (SERDs) — Dr Kalinsky...


Oct 25, 2024

Featuring a slide presentation and related discussion from Dr Erika Hamilton, including the following topics:

  • Targeted therapies for ER-positive breast cancer (0:00)
  • Clinical data with oral selective estrogen receptor degraders (2:13)
  • Biological rationale for and mechanism of action of proteolysis-targeting chimeras...


Oct 25, 2024

Featuring an interview with Dr Erika Hamilton, including the following topics:

  • Pathophysiology and pharmacology of ER-positive breast cancer treatment (0:00)
  • Clinical evidence available with oral selective estrogen receptor degraders (3:46)
  • Mechanism of action of proteolysis-targeting chimeras (PROTACs) (13:22)
  • PROTACs...


Sep 25, 2024

Featuring a slide presentation and related discussion from Dr Tiffany A Traina, including the following topics:

  • Extended follow-up with pembrolizumab/chemotherapy for patients with previously untreated PD-L1-positive metastatic triple-negative breast cancer (mTNBC) (0:00)
  • ASCENT trial: Survival advantage...


Sep 25, 2024

Featuring an interview with Dr Tiffany A Traina, including the following topics:

  • Choice of chemotherapy to combine with first-line pembrolizumab for metastatic triple-negative breast cancer (mTNBC) (0:00)
  • Ongoing investigations of androgen receptor-targeting agents for metastatic breast cancer (mBC) (8:37)
  • Efficacy and...